Tivicay

RSS

dolutegravir

Authorised
This medicine is authorised for use in the European Union.

Overview

Tivicay is a medicine used together with other medicines to treat adults and children from 6 years of age who are infected with human immunodeficiency virus (HIV), a virus that causes acquired immune deficiency syndrome (AIDS).

Tivicay contains the active substance dolutegravir.

This EPAR was last updated on 30/04/2020

Authorisation details

Product details
Name
Tivicay
Agency product number
EMEA/H/C/002753
Active substance
dolutegravir
International non-proprietary name (INN) or common name
dolutegravir
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AX12
Publication details
Marketing-authorisation holder
ViiV Healthcare BV
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
16/01/2014
Contact address

Huis ter Heideweg 62
3705 LZ Zeist
The Netherlands

Product information

08/04/2020 Tivicay - EMEA/H/C/002753 - WS/1762

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
3 ratings